surgoncoКреативная хирургия и онкологияCreative surgery and oncology2076-30932307-0501Башкирский государственный медицинский университет10.24060/2076-3093-2023-13-1-77-86surgonco-774Research ArticleОБЗОР ЛИТЕРАТУРЫREVIEWSЭрибулин в реальной клинической практике при метастатическом раке молочной железыEribulin in Metastatic Breast Cancer: Actual Clinical Practicehttps://orcid.org/0000-0003-0996-5995СултанбаевА. В.SultanbaevA. V.

Султанбаев Александр Валерьевич — к.м.н., отдел противоопухолевой лекарственной терапии

Республика Башкортостан, Уфа

 

Alexander V. Sultanbaev — Cand. Sci. (Med.), Anticancer Drug Therapy Unit

Ufa

https://orcid.org/0000-0003-3734-2779МеньшиковК. В.MenshikovK. V.

Меньшиков Константин Викторович — к.м.н., доцент, кафедра онкологии с курсами онкологии и патологической анатомии ИДПО, отдел химиотерапии

 Республика Башкортостан, Уфа

Konstantin V. Menshikov — Cand. Sci. (Med.), Assoc. Prof., Department of Oncology with Courses of Oncology and Pathological Anatomy for Advanced Professional Education, Chemotherapy Unit

Ufa

https://orcid.org/0000-0003-1185-977XМусинШ. И.MusinSh. I.

Мусин Шамиль Исмагилович — к.м.н., хирургическое отделение № 6

Республика Башкортостан, Уфа

Shamil I. Musin — Cand. Sci. (Med.), Surgery Unit No. 6

Ufa

https://orcid.org/0000-0002-8665-8895МеньшиковаИ. А.MenshikovaI. A.

Меньшикова Ирина Асхатовна — к.м.н., доцент, кафедра биологической химии

Республика Башкортостан, Уфа

 

Irina A. Menshikova — Cand. Sci. (Med.), Assoc. Prof., Department of Biological Chemistry

Ufa

https://orcid.org/0000-0001-5926-0446СултанбаеваН. И.SultanbaevaN. I.

Султанбаева Надежда Ивановна — отделение противоопухолевой лекарственной терапии № 1

Республика Башкортостан, Уфа

 

Nadezhda I. Sultanbaeva — Anticancer Drug Therapy Unit No. 1

Ufa

https://orcid.org/0000-0003-1242-759XПоповаЕ. В.PopovaE. V.

Попова Екатерина Владимировна — амбулаторное отделение противоопухолевой лекарственной терапии (химиотерапии)

Республика Башкортостан, Уфа

Ekaterina V. Popova — Outpatient Antiсancer Drug Therapy Unit (Сhemotherapy)

Ufa

АскаровВ. Е.AskarovV. E.

Аскаров Вадим Евгеньевич — амбулаторное отделение противоопухолевой лекарственной терапии (химиотерапии)

Республика Башкортостан, Уфа

Vadim E. Askarov — Outpatient Antiсancer Drug Therapy Unit (Сhemotherapy)

Ufa

Республиканский клинический онкологический диспансерРоссияRepublican Clinical Oncology DispensaryRussian FederationРеспубликанский клинический онкологический диспансер; Башкирский государственный медицинский университетРоссияRepublican Clinical Oncology Dispensary; Bashkir State Medical UniversityRussian FederationБашкирский государственный медицинский университетРоссияBashkir State Medical UniversityRussian Federation2023050420231317786Copyright © Султанбаев А.В., Меньшиков К.В., Мусин Ш.И., Меньшикова И.А., Султанбаева Н.И., Попова Е.В., Аскаров В.Е., 20232023Султанбаев А.В., Меньшиков К.В., Мусин Ш.И., Меньшикова И.А., Султанбаева Н.И., Попова Е.В., Аскаров В.Е.Sultanbaev A.V., Menshikov K.V., Musin S.I., Menshikova I.A., Sultanbaeva N.I., Popova E.V., Askarov V.E.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.surgonco.ru/jour/article/view/774

Рак молочной железы является наиболее распространенным видом рака у женщин как в Российской Федерации, так и в США. Эрибулин, новый ингибитор динамики микротрубочек, используется в США, Европе и других странах по всему миру для лечения пациенток с прогрессирующим или мРМЖ, которые резистентны для других линий терапии. Мезилат эрибулина представляет собой структурно упрощенный синтетический аналог галихондрина В, натурального продукта, выделенного из морской губки Halichondria okadai. Механизм действия эрибулина — подавление динамики микротрубочек. Он связывается с плюсовыми концами микротрубочек и подавляет рост микротрубочек в межфазных клетках, не влияя на фазу укорочения и секвестры тубулина в непродуктивные агрегаты, приводящие к G2/M блокировке клеточного цикла и, в конечном счете, апоптозу после длительной митотической блокировки. В реальной клинической практике лечение получают самые разнообразные пациентки с массой сопутствующей патологии и более низким функциональным статусом. Приведенные данные свидетельствуют, что эрибулин продемонстрировал сопоставимые результаты с исследованием EMBRACE для более широкой и разнообразной когорты пациентов. Дальнейшие исследования эрибулина в реальной клинической практике, безусловно, откроют новые возможности в терапии метастатического РМЖ.

 

Breast cancer is the most common cancer in women, both in the Russian Federation and in the United States. Eribulin is a new microtubule inhibitor, used in the USA, Europe and other countries around the world to treat patients with advanced or metastatic breast cancer, resistant to other lines of therapy. Eribulin mesylate is a structurally simplified, synthetic analogue of halichondrin B, a substance derived from a marine sponge Halichondria okadai. The mechanism of action: eribulin inhibits the microtubule dynamics, binds to the plus ends of microtubules and inhibits microtubule growth in interphase cells, without affecting the shortening phase and tubulin sequesters into nonproductive aggregates, leading to G2/M cell-cycle block and eventual apoptotic cell death after prolonged mitotic blockage. A wide variety of patients with a number of comorbidities and lower functional status are treated in actual clinical practice. The reported data suggest that eribulin has demonstrated comparable results to the EMBRACE study for a wider and more diverse cohort of patients. Further studies of eribulin in actual clinical practice will certainly provide new opportunities for the treatment of metastatic breast cancer.

рак молочной железыметастазыэрибулинингибитор микротрубочекпротивоопухолевые средствахимиотерапиягалихондринbreast cancermetastaseseribulinmicrotubule inhibitoranticancer agentschemotherapyhalichondrinReferencesNational Cancer Institute. SEER Cancer Statistics Factsheets: female breast cancer. [cited 2022 Oct 21]. Available from: http://seer.cancer.gov/statfacts/html/breast.htmlNational Cancer Institute. SEER Cancer Statistics Factsheets: female breast cancer. [cited 2022 Oct 21]. Available from: http://seer.cancer.gov/statfacts/html/breast.htmlKawano S., Ito K., Yahata K., Kira K., Abe T., Akagi T., et al. A landmark in drug discovery based on complex natural product synthesis. Sci Rep. 2019;9(1):8656. DOI: 10.1038/s41598-019-45001-9Kawano S., Ito K., Yahata K., Kira K., Abe T., Akagi T., et al. A landmark in drug discovery based on complex natural product synthesis. Sci Rep. 2019;9(1):8656. DOI: 10.1038/s41598-019-45001-9Dybdal-Hargreaves N.F., Risinger A.L., Mooberry S.L. Eribulin mesylate: mechanism of action of a unique microtubule-targeting agent. Clin Cancer Res. 2015;21(11):2445–52. DOI: 10.1158/1078-0432. CCR-14-3252Dybdal-Hargreaves N.F., Risinger A.L., Mooberry S.L. Eribulin mesylate: mechanism of action of a unique microtubule-targeting agent. Clin Cancer Res. 2015;21(11):2445–52. DOI: 10.1158/1078-0432. CCR-14-3252Halaven (eribulin mesylate) injection, for intravenous use [prescribing information]. Eisai Inc., 2016.Halaven (eribulin mesylate) injection, for intravenous use [prescribing information]. Eisai Inc., 2016.Wang X., Liu S., Xue Y. Treatment strategy and safety of Eribulin in advanced breast cancer. J Coll Physicians Surg Pak. 2022;32(1):122–4. DOI: 10.29271/jcpsp.2022.01.122. PMID: 34983165Wang X., Liu S., Xue Y. Treatment strategy and safety of Eribulin in advanced breast cancer. J Coll Physicians Surg Pak. 2022;32(1):122–4. DOI: 10.29271/jcpsp.2022.01.122. PMID: 34983165O'Shaughnessy J., Kaklamani V., Kalinsky K. Perspectives on the mechanism of action and clinical application of eribulin for metastatic breast cancer. Future Oncol. 2019;15(14):1641–53. DOI: 10.2217/fon2018-0936O'Shaughnessy J., Kaklamani V., Kalinsky K. Perspectives on the mechanism of action and clinical application of eribulin for metastatic breast cancer. Future Oncol. 2019;15(14):1641–53. DOI: 10.2217/fon2018-0936Halaven 0.44 mg/ml solution for injection [summary of product characteristics]. Hertfordshire: Eisai Europe Limited; 2017.Halaven 0.44 mg/ml solution for injection [summary of product characteristics]. Hertfordshire: Eisai Europe Limited; 2017.Pedersini R., di Mauro P., Amoroso V., Parati M.C., Turla A., Ghilardi M., et al. Efficacy of Eribulin mesylate in older patients with breast cancer: A pooled analysis of clinical trial and real-world data. J Geriatr Oncol. 2020;11(6):976–81. DOI: 10.1016/j.jgo.2020.03.021Pedersini R., di Mauro P., Amoroso V., Parati M.C., Turla A., Ghilardi M., et al. Efficacy of Eribulin mesylate in older patients with breast cancer: A pooled analysis of clinical trial and real-world data. J Geriatr Oncol. 2020;11(6):976–81. DOI: 10.1016/j.jgo.2020.03.021López González A., Del Barco Berrón S., Grau I., Galan M., Castelo Fernández B., Cortés A., et al. Challenging endocrine sensitivity of hormone receptor-positive/HER2-negative advanced breast cancer with the combination of eribulin and endocrine therapy: the REVERT study. Cancers (Basel). 2022;14(23):5880. DOI: 10.3390/cancers14235880López González A., Del Barco Berrón S., Grau I., Galan M., Castelo Fernández B., Cortés A., et al. Challenging endocrine sensitivity of hormone receptor-positive/HER2-negative advanced breast cancer with the combination of eribulin and endocrine therapy: the REVERT study. Cancers (Basel). 2022;14(23):5880. DOI: 10.3390/cancers14235880Pellegrino B., Cavanna L., Boggiani D., Zamagni C., Frassoldati A., Schirone A., et al. Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC). ESMO Open. 2021;6(1):100019. DOI: 10.1016/j.esmoop.2020.100019Pellegrino B., Cavanna L., Boggiani D., Zamagni C., Frassoldati A., Schirone A., et al. Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC). ESMO Open. 2021;6(1):100019. DOI: 10.1016/j.esmoop.2020.100019Olatunde O.Z., Yong J., Lu C. The progress of the anticancer agents related to the microtubules target. Mini Rev Med Chem. 2020;20(20):2165–92. DOI: 10.2174/1389557520666200729162510Olatunde O.Z., Yong J., Lu C. The progress of the anticancer agents related to the microtubules target. Mini Rev Med Chem. 2020;20(20):2165–92. DOI: 10.2174/1389557520666200729162510Okouneva T., Azarenko O., Wilson L., Littlefield B.A., Jordan M.A. Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase. Mol. Cancer Ther. 2008;7(7):2003–11. DOI: 10.1158/15357163.MCT-08-0095Okouneva T., Azarenko O., Wilson L., Littlefield B.A., Jordan M.A. Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase. Mol. Cancer Ther. 2008;7(7):2003–11. DOI: 10.1158/15357163.MCT-08-0095Smith J.A., Wilson L., Azarenko O., Zhu X., Lewis B.M., Littlefield B.A., et al. Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability. Biochemistry. 2010;49(6):1331–7. DOI: 10.1021/bi901810uSmith J.A., Wilson L., Azarenko O., Zhu X., Lewis B.M., Littlefield B.A., et al. Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability. Biochemistry. 2010;49(6):1331–7. DOI: 10.1021/bi901810uKenny L., Beresford M., Brown I., Misra V., Kristeleit H. Eribulin for the treatment of advanced breast cancer: A prospective observational registry study. Eur J Cancer Care (Engl). 2022;31(6):e13747. DOI: 10.1111/ecc.13747Kenny L., Beresford M., Brown I., Misra V., Kristeleit H. Eribulin for the treatment of advanced breast cancer: A prospective observational registry study. Eur J Cancer Care (Engl). 2022;31(6):e13747. DOI: 10.1111/ecc.13747Kashiwagi S., Asano Y., Goto W., Takada K., Morisaki T., Kouhashi R., et al. Validation of systemic and local tumour immune response to eribulin chemotherapy in the treatment of breast cancer. Anticancer Res. 2020;40(6):3345–54. DOI: 10.21873/anticanres.14317Kashiwagi S., Asano Y., Goto W., Takada K., Morisaki T., Kouhashi R., et al. Validation of systemic and local tumour immune response to eribulin chemotherapy in the treatment of breast cancer. Anticancer Res. 2020;40(6):3345–54. DOI: 10.21873/anticanres.14317Uemura D., Takahashi K., Yamamoto T., Katayama C., Tanaka J., Okumura Y., et al. Norhalichondrin A: An antitumor polyether macrolide from a marine sponge. J Am Chem Soc. 1985;107(16):4796–8. DOI: 10.1021/ja00302a042Uemura D., Takahashi K., Yamamoto T., Katayama C., Tanaka J., Okumura Y., et al. Norhalichondrin A: An antitumor polyether macrolide from a marine sponge. J Am Chem Soc. 1985;107(16):4796–8. DOI: 10.1021/ja00302a042Swami U., Chaudhary I., Ghalib M.H., Goel S. Eribulin — A review of preclinical and clinical studies. Crit Rev Oncol Hematol. 2012;81(2):163–84. DOI: 10.1016/j.critrevonc.2011.03.002Swami U., Chaudhary I., Ghalib M.H., Goel S. Eribulin — A review of preclinical and clinical studies. Crit Rev Oncol Hematol. 2012;81(2):163–84. DOI: 10.1016/j.critrevonc.2011.03.002Donoghue M., Lemery S.J., Yuan W., He K., Sridhara R., Shord S., et al. Eribulin mesylate for the treatment of patients with refractory metastatic breast cancer: Use of a “physician’s choice” control arm in a randomized approval trial. Clin Cancer Res. 2012;18(6):1496–505. DOI: 10.1158/1078-0432.CCR-11-2149.Donoghue M., Lemery S.J., Yuan W., He K., Sridhara R., Shord S., et al. Eribulin mesylate for the treatment of patients with refractory metastatic breast cancer: Use of a “physician’s choice” control arm in a randomized approval trial. Clin Cancer Res. 2012;18(6):1496–505. DOI: 10.1158/1078-0432.CCR-11-2149.Jordan M.A., Kamath K., Manna T., Okouneva T., Miller H.P., Davis C., et al. The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther. 2005;4(7):1086–95. DOI: 10.1158/1535-7163.MCT-04-0345Jordan M.A., Kamath K., Manna T., Okouneva T., Miller H.P., Davis C., et al. The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther. 2005;4(7):1086–95. DOI: 10.1158/1535-7163.MCT-04-0345Tan A.R., Rubin E.H., Walton D.C., Shuster D.E., Wong Y.N., Fang F., et al. Phase I study of eribulin mesylate administered once every days in patients with advanced solid tumors. Clin Cancer Res. 2009;15(12):4213–9. DOI: 10.1158/1078-0432.CCR-09-0360Tan A.R., Rubin E.H., Walton D.C., Shuster D.E., Wong Y.N., Fang F., et al. Phase I study of eribulin mesylate administered once every days in patients with advanced solid tumors. Clin Cancer Res. 2009;15(12):4213–9. DOI: 10.1158/1078-0432.CCR-09-0360de Nonneville A., Sabatier R., Gonçalves A., Extra J.M., Tarpin C., Launay S., et al. Safety and efficacy of eribulin for "real-world" older patients with metastatic breast cancer. J Geriatr Oncol. 2018;9(3):281–3. DOI: 10.1016/j.jgo.2017.11.003de Nonneville A., Sabatier R., Gonçalves A., Extra J.M., Tarpin C., Launay S., et al. Safety and efficacy of eribulin for "real-world" older patients with metastatic breast cancer. J Geriatr Oncol. 2018;9(3):281–3. DOI: 10.1016/j.jgo.2017.11.003Fukada I., Ito Y., Kondo N., Ohtani S., Hattori M., Tokunaga E., et al. A phase II study of sequential treatment with anthracycline and taxane followed by eribulin in patients with HER2-negative, locally advanced breast cancer (JBCRG-17). Breast Cancer Res Treat. 2021;190(3):425– 34. DOI: 10.1007/s10549-021-06396-0Fukada I., Ito Y., Kondo N., Ohtani S., Hattori M., Tokunaga E., et al. A phase II study of sequential treatment with anthracycline and taxane followed by eribulin in patients with HER2-negative, locally advanced breast cancer (JBCRG-17). Breast Cancer Res Treat. 2021;190(3):425– 34. DOI: 10.1007/s10549-021-06396-0Towle M.J., Salvato K.A., Budrow J., Wels B.F., Kuznetsov G., Aalfs K.K., et al. In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res. 2001;61:1013– 21. PMID: 11221827Towle M.J., Salvato K.A., Budrow J., Wels B.F., Kuznetsov G., Aalfs K.K., et al. In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res. 2001;61:1013– 21. PMID: 11221827Aogi K., Iwata H., Masuda N., Mukai H., Yoshida M., Rai Y., et al. A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer. Ann Oncol. 2012;23(6):1441–8. DOI: 10.1093/ annonc/mdr444Aogi K., Iwata H., Masuda N., Mukai H., Yoshida M., Rai Y., et al. A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer. Ann Oncol. 2012;23(6):1441–8. DOI: 10.1093/ annonc/mdr444Cortes J., Vahdat L., Blum J.L., Twelves C., Campone M., Roché H., et al. Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously reated with an anthracycline, a taxane, and capecitabine. J Clin Oncol. 2010;28(25):3922–8. DOI: 10.1200/JCO.2009.25.8467Cortes J., Vahdat L., Blum J.L., Twelves C., Campone M., Roché H., et al. Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously reated with an anthracycline, a taxane, and capecitabine. J Clin Oncol. 2010;28(25):3922–8. DOI: 10.1200/JCO.2009.25.8467Vahdat L.T., Pruitt B., Fabian C.J., Rivera R.R., Smith D.A., Tan-Chiu E., et al. Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2009;27(18):2954–61. DOI: 10.1200/JCO.2008.17.7618Vahdat L.T., Pruitt B., Fabian C.J., Rivera R.R., Smith D.A., Tan-Chiu E., et al. Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2009;27(18):2954–61. DOI: 10.1200/JCO.2008.17.7618Cortes J., O'Shaughnessy J., Loesch D., Blum J.L., Vahdat L.T., Petrakova K., et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet. 2011;377(9769):914–23. DOI: 10.1016/S0140-6736(11)60070-6Cortes J., O'Shaughnessy J., Loesch D., Blum J.L., Vahdat L.T., Petrakova K., et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet. 2011;377(9769):914–23. DOI: 10.1016/S0140-6736(11)60070-6Twelves C., Cortes J., Vahdat L.T., Wanders J., Akerele C., Kaufman P.A. Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer. Clin Breast Cancer. 2010;10(2):160–3. DOI: 10.3816/CBC.2010.n.023Twelves C., Cortes J., Vahdat L.T., Wanders J., Akerele C., Kaufman P.A. Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer. Clin Breast Cancer. 2010;10(2):160–3. DOI: 10.3816/CBC.2010.n.023Greenhalgh J., Bagust A., Boland A., Oyee J., Trevor N., Beale S., et al. Eribulin for the treatment of advanced or metastatic breast cancer: a NICE single technology appraisal. Pharmacoeconomics. 2015;33(2):137–48. DOI: 10.1007/s40273-014-0214-2Greenhalgh J., Bagust A., Boland A., Oyee J., Trevor N., Beale S., et al. Eribulin for the treatment of advanced or metastatic breast cancer: a NICE single technology appraisal. Pharmacoeconomics. 2015;33(2):137–48. DOI: 10.1007/s40273-014-0214-2Kaufman P.A., Awada A., Twelves C., Yelle L., Perez E.A., Velikova G., et al. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2015;33(6):594–601. DOI: 10.1200/JCO.2013.52.4892Kaufman P.A., Awada A., Twelves C., Yelle L., Perez E.A., Velikova G., et al. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2015;33(6):594–601. DOI: 10.1200/JCO.2013.52.4892Manso L., Moreno Antón F., Izarzugaza Perón Y., Delgado Mingorance J.I., Borrega García P., Echarri González M.J., et al. Safety of eribulin as third-line chemotherapy in HER2-negative, advanced breast cancer pre-treated with taxanes and anthracycline: OnSITE study. Breast J. 2019;25(2):219–25. DOI: 10.1111/tbj.13199Manso L., Moreno Antón F., Izarzugaza Perón Y., Delgado Mingorance J.I., Borrega García P., Echarri González M.J., et al. Safety of eribulin as third-line chemotherapy in HER2-negative, advanced breast cancer pre-treated with taxanes and anthracycline: OnSITE study. Breast J. 2019;25(2):219–25. DOI: 10.1111/tbj.13199Sang D., Song L.H., Di L.J., Wang Y.L., Liu C.G., Guo Z.Q., et al. Multicenter real world study on the efficacy and safety of eribulin for the treatment of advanced breast cancer. Zhonghua Zhong Liu Za Zhi. 2022;44(4):364–9. DOI: 10.3760/cma.j.cn112152-20210226-00173Sang D., Song L.H., Di L.J., Wang Y.L., Liu C.G., Guo Z.Q., et al. Multicenter real world study on the efficacy and safety of eribulin for the treatment of advanced breast cancer. Zhonghua Zhong Liu Za Zhi. 2022;44(4):364–9. DOI: 10.3760/cma.j.cn112152-20210226-00173Hayashida T., Jinno H., Mori K., Sato H., Matsui A., Sakurai T., et al. Phase II trial of eribulin mesylate as a firstor second-line treatment for locally advanced or metastatic breast cancer: a multicenter, singlearm trial. BMC Cancer. 2018;18(1):701. DOI: 10.1186/s12885-0184628-7Hayashida T., Jinno H., Mori K., Sato H., Matsui A., Sakurai T., et al. Phase II trial of eribulin mesylate as a firstor second-line treatment for locally advanced or metastatic breast cancer: a multicenter, singlearm trial. BMC Cancer. 2018;18(1):701. DOI: 10.1186/s12885-0184628-7Yamashita T., Kawaguchi H., Masuda N., Kitada M., Narui K., Hattori M., et al. Efficacy of the eribulin, pertuzumab, and trastuzumab combination therapy for human epidermal growth factor receptor 2-positive advanced or metastatic breast cancer: a multicenter, single arm, phase II study (JBCRG-M03 study). Invest New Drugs. 2021;39(1):217–25. DOI: 10.1007/s10637-020-00991-6Yamashita T., Kawaguchi H., Masuda N., Kitada M., Narui K., Hattori M., et al. Efficacy of the eribulin, pertuzumab, and trastuzumab combination therapy for human epidermal growth factor receptor 2-positive advanced or metastatic breast cancer: a multicenter, single arm, phase II study (JBCRG-M03 study). Invest New Drugs. 2021;39(1):217–25. DOI: 10.1007/s10637-020-00991-6De Angelis C., Bruzzese D., Bernardo A., Baldini E., Leo L., Fabi A., et al. Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI). ESMO Open. 2021;6(2):100097. DOI: 10.1016/j.esmoop.2021.100054De Angelis C., Bruzzese D., Bernardo A., Baldini E., Leo L., Fabi A., et al. Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI). ESMO Open. 2021;6(2):100097. DOI: 10.1016/j.esmoop.2021.100054National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Cancer Stat Facts: Female Breast Cancer Subtypes. [cited 2020 June 4]. Available from: https://seer.cancer.gov/statfacts/html/breastsubtypes.htmlNational Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Cancer Stat Facts: Female Breast Cancer Subtypes. [cited 2020 June 4]. Available from: https://seer.cancer.gov/statfacts/html/breastsubtypes.htmlMougalian S.S., Kish J.K., Zhang J., Liassou D., Feinberg B.A. Effectiveness of eribulin in metastatic breast cancer: 10 years of real-world clinical experience in the United States. Adv Ther. 2021;38(5):2213–25. DOI: 10.1007/s12325-020-01613-6Mougalian S.S., Kish J.K., Zhang J., Liassou D., Feinberg B.A. Effectiveness of eribulin in metastatic breast cancer: 10 years of real-world clinical experience in the United States. Adv Ther. 2021;38(5):2213–25. DOI: 10.1007/s12325-020-01613-6Филоненко Д.В., Белоногов А.В. Опыт применения эрибулина в условиях реальной клинической практики. Злокачественные опухоли. 2017;7(4):21–8. DOI:10.18027/2224-5057-2017-7-4-21-28Filonenko D.V., Belonogov A.V. Eribulin mesylate: our experience in a real-life clinical setting. Malignant Tumours. 2017;7(4):21–8 (In Russ.). DOI: 10.18027/2224-5057-2017-7-4-21-28Watanabe J., Ito Y., Ohsumi S., Mizutani M., Tashiro H., Sakurai K., et al. Safety and effectiveness of eribulin in Japanese patients with locally advanced or metastatic breast cancer: a post-marketing ob-servational study. Investig New Drugs. 2017;35:791–9. DOI: 10.1007/s10637-0170486-4Watanabe J., Ito Y., Ohsumi S., Mizutani M., Tashiro H., Sakurai K., et al. Safety and effectiveness of eribulin in Japanese patients with locally advanced or metastatic breast cancer: a post-marketing ob-servational study. Investig New Drugs. 2017;35:791–9. DOI: 10.1007/s10637-0170486-4Maeda S., Saimura M., Minami S., Kurashita K., Nishimura R., Kai Y., et al. Efficacy and safety of eribulin as firstto third-line treatment in patients with advanced or metastatic breast cancer previously treated with anthracyclines and taxanes. Breast. 2017;32:66–72. DOI: 10.1016/j.breast.2016.12.017Maeda S., Saimura M., Minami S., Kurashita K., Nishimura R., Kai Y., et al. Efficacy and safety of eribulin as firstto third-line treatment in patients with advanced or metastatic breast cancer previously treated with anthracyclines and taxanes. Breast. 2017;32:66–72. DOI: 10.1016/j.breast.2016.12.017Chen P.H., Yeh D.C., Tung H.H., Lin C.Y. Prognostic and predictive factors of eribulin in patients with heavily pre-treated metastatic breast cancer. Medicine (Baltimore). 2021;100(47):e27859. DOI: 10.1097/ MD.0000000000027859Chen P.H., Yeh D.C., Tung H.H., Lin C.Y. Prognostic and predictive factors of eribulin in patients with heavily pre-treated metastatic breast cancer. Medicine (Baltimore). 2021;100(47):e27859. DOI: 10.1097/ MD.0000000000027859Pivot X., Im S.A., Guo M., Marmé F. Subgroup analysis of patients with HER2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabine. Breast Cancer. 2018;25(3):370–4. DOI: 10.1007/s12282017-0826-4Pivot X., Im S.A., Guo M., Marmé F. Subgroup analysis of patients with HER2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabine. Breast Cancer. 2018;25(3):370–4. DOI: 10.1007/s12282017-0826-4Inoue K., Saito T., Okubo K., Kimizuka K., Yamada H., Sakurai T., et al. Phase II clinical study of eribulin monotherapy in Japanese patients with metastatic breast cancer who had well-defined taxane resistance. Breast Cancer Res Treat. 2016;157:295–305. DOI: 10.1007/ s10549-016-3808-xInoue K., Saito T., Okubo K., Kimizuka K., Yamada H., Sakurai T., et al. Phase II clinical study of eribulin monotherapy in Japanese patients with metastatic breast cancer who had well-defined taxane resistance. Breast Cancer Res Treat. 2016;157:295–305. DOI: 10.1007/ s10549-016-3808-xWatanabe J. Eribulin monotherapy improved survivals in patients with ER-positive HER2-negative metastatic breast cancer in the real world: a single institutional review. Springerplus. 2015;4:625. DOI: 10.1186/ s40064-015-1422-8Watanabe J. Eribulin monotherapy improved survivals in patients with ER-positive HER2-negative metastatic breast cancer in the real world: a single institutional review. Springerplus. 2015;4:625. DOI: 10.1186/ s40064-015-1422-8Kikuchi Y., Uchida Y., Shirakawa K., Kanauchi H., Niwa T., Nishioka K., et al. A multicenter, observational study of metastatic breast cancer patients who were treated with eribulin mesylate or taxane-based regimens. Asia Pac J Clin Oncol. 2018;14:e231–7. DOI: 10.1111/ajco.12863Kikuchi Y., Uchida Y., Shirakawa K., Kanauchi H., Niwa T., Nishioka K., et al. A multicenter, observational study of metastatic breast cancer patients who were treated with eribulin mesylate or taxane-based regimens. Asia Pac J Clin Oncol. 2018;14:e231–7. DOI: 10.1111/ajco.12863Inoue K., Takahashi M., Mukai H., Yamanaka T., Egawa C., Sakata Y., et al. Effectiveness and safety of eribulin in Japanese patients with HER2negative, advanced breast cancer: a 2-year post-marketing observational study in a real-world setting. Invest New Drugs. 2020;38(5):1540–9. DOI: 10.1007/s10637-019-00890-5Inoue K., Takahashi M., Mukai H., Yamanaka T., Egawa C., Sakata Y., et al. Effectiveness and safety of eribulin in Japanese patients with HER2negative, advanced breast cancer: a 2-year post-marketing observational study in a real-world setting. Invest New Drugs. 2020;38(5):1540–9. DOI: 10.1007/s10637-019-00890-5

The authors declare that there are no conflicts of interest present.